These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 20390419)

  • 1. A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma.
    Kanai F; Yoshida H; Tateishi R; Sato S; Kawabe T; Obi S; Kondo Y; Taniguchi M; Tagawa K; Ikeda M; Morizane C; Okusaka T; Arioka H; Shiina S; Omata M
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):315-24. PubMed ID: 20390419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma.
    Ikeda M; Shiina S; Nakachi K; Mitsunaga S; Shimizu S; Kojima Y; Ueno H; Morizane C; Kondo S; Sakamoto Y; Asaoka Y; Tateishi R; Koike K; Arioka H; Okusaka T
    Invest New Drugs; 2014 Oct; 32(5):928-36. PubMed ID: 24829073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolisation.
    Inaba Y; Kanai F; Aramaki T; Yamamoto T; Tanaka T; Yamakado K; Kaneko S; Kudo M; Imanaka K; Kora S; Nishida N; Kawai N; Seki H; Matsui O; Arioka H; Arai Y
    Eur J Cancer; 2013 Sep; 49(13):2832-40. PubMed ID: 23764238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer.
    Yoo C; Kim SB; Ro J; Im SA; Im YH; Kim JH; Ahn JH; Jung KH; Song HS; Kang SY; Park HS; Chung HC
    Cancer Res Treat; 2016 Apr; 48(2):499-507. PubMed ID: 26194374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors.
    Murakami H; Ueda Y; Shimoyama T; Yamamoto N; Yamada Y; Arioka H; Tamura T
    Cancer Chemother Pharmacol; 2011 May; 67(5):1119-28. PubMed ID: 20676674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
    McNamara MG; Le LW; Horgan AM; Aspinall A; Burak KW; Dhani N; Chen E; Sinaei M; Lo G; Kim TK; Rogalla P; Bathe OF; Knox JJ
    Cancer; 2015 May; 121(10):1620-7. PubMed ID: 25565269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times.
    Enooku K; Tateishi R; Kanai F; Kondo Y; Masuzaki R; Goto T; Shiina S; Yoshida H; Omata M; Koike K
    J Gastroenterol; 2012 Jan; 47(1):71-8. PubMed ID: 21935635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma.
    Toh HC; Chen PJ; Carr BI; Knox JJ; Gill S; Ansell P; McKeegan EM; Dowell B; Pedersen M; Qin Q; Qian J; Scappaticci FA; Ricker JL; Carlson DM; Yong WP
    Cancer; 2013 Jan; 119(2):380-7. PubMed ID: 22833179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane.
    Suzuki Y; Saeki T; Aogi K; Toi M; Fujii H; Inoue K; Watanabe T; Fujiwara Y; Ito Y; Takatsuka Y; Iwata H; Arioka H; Tokuda Y
    Int J Clin Oncol; 2013 Aug; 18(4):590-7. PubMed ID: 22585426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors.
    Ueda Y; Shimoyama T; Murakami H; Yamamoto N; Yamada Y; Arioka H; Tamura T
    Cancer Chemother Pharmacol; 2011 May; 67(5):1101-9. PubMed ID: 20676675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib.
    Harmon CS; DePrimo SE; Raymond E; Cheng AL; Boucher E; Douillard JY; Lim HY; Kim JS; Lechuga MJ; Lanzalone S; Lin X; Faivre S
    J Transl Med; 2011 Jul; 9():120. PubMed ID: 21787417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment.
    Okusaka T; Otsuka T; Ueno H; Mitsunaga S; Sugimoto R; Muro K; Saito I; Tadayasu Y; Inoue K; Loembé AB; Ikeda M
    Cancer Sci; 2016 Dec; 107(12):1791-1799. PubMed ID: 27627050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.
    Zhu AX; Sahani DV; Duda DG; di Tomaso E; Ancukiewicz M; Catalano OA; Sindhwani V; Blaszkowsky LS; Yoon SS; Lahdenranta J; Bhargava P; Meyerhardt J; Clark JW; Kwak EL; Hezel AF; Miksad R; Abrams TA; Enzinger PC; Fuchs CS; Ryan DP; Jain RK
    J Clin Oncol; 2009 Jun; 27(18):3027-35. PubMed ID: 19470923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
    Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
    Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
    Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
    J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TSU-68 ameliorates hepatocellular carcinoma growth by inhibiting microenvironmental platelet-derived growth factor signaling.
    Hara Y; Yamashita T; Oishi N; Nio K; Hayashi T; Nomura Y; Yoshida M; Hayashi T; Hashiba T; Asahina Y; Kondo M; Okada H; Sunagozaka H; Honda M; Kaneko S
    Anticancer Res; 2015 Mar; 35(3):1423-31. PubMed ID: 25750293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).
    Koeberle D; Montemurro M; Samaras P; Majno P; Simcock M; Limacher A; Lerch S; Kovàcs K; Inauen R; Hess V; Saletti P; Borner M; Roth A; Bodoky G
    Oncologist; 2010; 15(3):285-92. PubMed ID: 20203173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib: a review of its use in advanced hepatocellular carcinoma.
    Keating GM; Santoro A
    Drugs; 2009; 69(2):223-40. PubMed ID: 19228077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer.
    Okamoto I; Yoshioka H; Takeda K; Satouchi M; Yamamoto N; Seto T; Kasahara K; Miyazaki M; Kitamura R; Ohyama A; Hokoda N; Nakayama H; Yoshihara E; Nakagawa K
    J Thorac Oncol; 2012 Feb; 7(2):427-33. PubMed ID: 22071785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma.
    Simonelli M; Zucali P; Santoro A; Thomas MB; de Braud FG; Borghaei H; Berlin J; Denlinger CS; Noberasco C; Rimassa L; Kim TY; English PA; Abbattista A; Gallo Stampino C; Carpentieri M; Williams JA
    Ann Oncol; 2016 Sep; 27(9):1782-7. PubMed ID: 27329247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.